MAKSci­en­tific, LLC, a pri­vately held com­pany in Boston focused on the dis­covery of novel ther­a­peu­tics mod­u­lating cannabi­noid path­ways, today announced that it has entered into an exclu­sive option and col­lab­o­ra­tion agree­ment with Biogen Idec (NASDAQ: BIIB) to develop and com­mer­cialize drug can­di­dates for the treat­ment of mul­tiple scle­rosis (MS) and other neu­rode­gen­er­a­tive diseases.

Read the article at Mass High Tech →